The Ohio State University
Columbus, Ohio, 43210, United States
NCT Number: NCT02088190
The investigators hypothesize that the improvements in insulin sensitivity, beta (β)-cell function, and inflammation will be greater, and the improvement in sarcopenic obesity will be less, in younger versus older individuals after substantial weight loss induced by sleeve gastrectomy bariatric surgery.
Looking for future studies?
Notify Me21 year–80 year
All sexes
Observational
Columbus, Ohio, 43210, United States
With an aging population that is increasingly susceptible to obesity and obesity-related comorbidities including sarcopenia and diabetes, effective and safe treatment options tailored to the needs of older adults are imperative. While medication and lifestyle interventions generally fail to achieve sustained large-scale weight loss, bariatric surgery is the most effective long-term weight loss treatment for obese patients and improves many of the medical complications associated with obesity. Sleeve gastrectomy (SG) results in substantial weight loss and may be more appropriate for older adults due to its low rate of complications and mortality. Therefore, SG has been proposed as a reasonable primary treatment modality in older obese individuals, with a substantial recent increase in the number of interventions performed. Despite the potential benefits, very little is known of the physiologic and metabolic effects of bariatric surgery, including SG, on glucose homeostasis and muscle physiology in older adults. A fundamental understanding of the effects of excess adiposity and weight loss interventions is of profound importance, especially with emerging evidence that earlier treatment of obesity may delay/prevent many comorbidities. An underlying inflammatory state has been implicated in the pathogenesis of sarcopenia and insulin resistance and may provide an important connection to the age-related declines seen in older obese patients. Therefore, this study aims to evaluate the modifying effect of age and inflammation on the SG-induced changes in body composition, muscle physiology, and insulin sensitivity. This protocol will be conducted in two age cohorts (greater than 60 and less than 50 years old).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Type of bariatric surgery
Time frame: Change from baseline in Insulin sensitivity at 15% weight loss (up to 4 months after surgery)
Subjects will undergo a clamp procedure to assess insulin sensitivity at baseline and 15% weight loss after surgery
Time frame: Change from baseline to 15% weight loss (up to 4 months after surgery)
Subjects will undergo a mixed meal tolerance test at baseline and 15% weight loss
Ohio State University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06242535
Behavior, Behavioral Symptoms
Gillette, Wyoming, United States
View Trial DetailsNCT00231894
Cognition Disorders, Cognitive Dysfunction
New York, United States
View Trial DetailsNCT06912321
Cognition Disorders, Cognitive Dysfunction
Nanjing, Jiangsu, China
View Trial DetailsNCT02984540
Cognition Disorders, Cognitive Dysfunction
Winston-Salem, North Carolina, United States
View Trial Details